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Kathryn B. Garber1,*NF1-like Syndrome Really Isn’t Much Like NF1
Diagnosis of neuroﬁbromatosis type 1 (NF1) is made clini-
cally through the use of a well-established set of diagnostic
criteria. Two of the key features included in these criteria
are the presence of more than ﬁve cafe´-au-lait macules
and of axillary or inguinal freckling. The more serious
features of this syndrome include neuroﬁbromas and
bone lesions. Legius syndrome (formerly known as NF1-
like syndrome) is due tomutations in SPRED1 and overlaps
clinically with NF1 in that affected individuals also
commonly have multiple cafe´-au-lait macules as well as
inguinal and axillary freckling. To better understand the
full phenotypic spectrum of Legius syndrome, Messiaen
et al. used a two-pronged approach to collect the largest
set of SPRED1 mutation-positive individuals to date.
They used data from their clinical testing lab on patients
referred for SPRED1 mutation testing, as well as a set of
more than 1300 anonymous samples from individuals
with features of NF1 but no detectableNF1mutation. Their
data show that many people with Legius syndrome could
be erroneously given a diagnosis of NF1. In the ﬁrst compo-
nent of the study, nearly half of their SPRED1 mutation-
positive individuals met the clinical criteria for NF1,
although they did not, in fact, have the disease. The impor-
tance of distinguishing these related diseases is that the
severity of Legius syndrome appears to be much lower
than that of NF1; none of the individuals who had muta-
tions in SPRED1 had neuroﬁbromas, osseous lesions, or a
symptomatic optic pathway glioma. Thus, the authors
recommend that SPRED1mutation testing is an important
consideration in NF1 mutation-negative individuals who
have cafe´-au-lait spots with or without freckling but who
lack other NF1 diagnostic features.
Messiaen et al. (2009) Clinical and mutational spectrum of
neuroﬁbromatosis type1-like syndrome. JAMA302,2111–2118.
Five Years of Data on ERT for Fabry Disease
Fabry disease is a lysosomal-storage disorder whose key
morbidity and mortality result from renal and cardiac
disease. Enzyme replacement therapy (ERT) became
available in the early 2000s and has proven to be effective
in randomized controlled trials. Now, some of the ﬁrst
long-term data on ERT are becoming available. Mehta
et al. report ﬁve years of observational data on agalsidase
alfa for Fabry disease, which were collected as part of a
multinational registry, the Fabry Outcome Survey. Base-1Department of Human Genetics, Emory University School of Medicine, Atlan
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Thline and ﬁve-year data were available for 181 adults in this
registry. Treatment with agalsidase alpha over ﬁve years
had positive effects on Fabry disease progression. ERT led
to sustained reductions in left ventricular mass and
increased cardiac contractility in patients who had cardiac
hypertrophy at baseline, as well as stable measurements
of both in those without baseline hypertrophy. The treat-
ment slowed the decline of glomerular ﬁltration rates as
compared to what is expected for the natural course
of disease, and it was associated with reduced pain and
increasedquality of life. Although there are inherent limita-
tions to large, observational studies such as this one, these
data provide additional evidence for the long-term safety
and efﬁcacy of agalsidase alfa for treatment of Fabry disease.
Mehta et al. (2009) Enzyme replacement therapy with
agalsidase alfa in patients with Fabry’s disease: An analysis
of registry data. Lancet. Published online December 2, 2009.
10.1016/S0140-6736(09)61494-8.
Separating the Haves from the Have-Nots
When bone marrow transplants are performed, attempts
are made tomatch the donors with the recipients to ensure
histocompatibility between the two. Even with HLA-iden-
tical siblings, however, the risk of graft-versus-host disease
(GVHD) is still quite high. McCarroll et al. noticed that
surveys of copy-number variation (CNV) have revealed
whole-gene deletions that can be quite common in a pop-
ulation, and they wondered: Could these be the key to
GVHD? If a bone marrow donor does not express a protein
because he is homozygous for a deletion CNV, whereas the
recipient expresses the protein, would the engrafted bone
marrow recognize the protein as foreign and generate a
GVHD response? To explore this hypothesis, they selected
a set of six common deletion alleles that are expressed in
the tissues relevant to acute GVHD, and they genotyped
these deletions in a set of bone marrow transplantation
donor-recipient pairs. Donor-recipientmismatch for a dele-
tion encompassing UGT2B17 was associated with risk for
GVHD, a ﬁnding that was replicated in additional samples.
In further support of the role of UGT2B17 in GVHD, T cells
and sera from some patients with GVHD recognized
peptides from the encoded protein. Although the odds
ratio of GVHD associated with mismatch at UGT2B17 is
2.5, the rate of sibling mismatch at this locus will be less
than 10%, so this locus can explain only a small fraction
of GVHD. However, this paradigm could hold true at otherta, GA 30322, USA
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loci, and it is plausible that, when considered together,
CNV could have a large impact on GVHD.
McCarroll et al. (2009) Donor-recipient mismatch for
common gene deletion polymorphisms in graft-versus-host
disease Nature Genetics I, 1341–1345.
A Nod to Autophagy
Variation in NOD2 and ATG16L1 are each associated with
risk of Crohn disease, an inﬂammatory disease of the gut.
NOD2 is a pattern-recognition receptor that helps the
body recognize foreign invaders, whereas ATG16L1
encodes a protein that is involved in autophagy. Cooney
et al. identify a previously unknown link between the
two processes that helps explain how these seemingly
disparate pathways can both inﬂuence Crohn’s disease.
They show that the bacterial ligand of NOD2, muramyldi-
peptide, can stimulate autophagy in dendritic cells, and
this process inﬂuences MHC class II antigen presentation
by these cells. Dendritic cells from individuals who carry
variation in NOD2 or in ATG16L1 that is associated with
Crohn disease show defects in both of these processes, as
well as a reduced ability to control intracellular bacterial
infections. This connects two strong genetic risk factors
for Crohn disease into a single pathway and further
speciﬁes the connection between Crohn disease and
aberrant inﬂammatory responses.
Cooney et al. (2009) NOD2 stimulation induces autophagy
in dendritic cells inﬂuencing bacterial handling and antigen
presentation. Nature Medicine. Published online December 6,
2009. 10.1038/nm.2069.4 The American Journal of Human Genetics 86, 3–5, January 8, 2010Molecular Mechanism for Alpha2A-Adrenergic
Receptor in Type 2 Diabetes
Genome-wide association studies are all the rage, and they
have produced some very exciting results over the past
few years. However, we shouldn’t forget the very powerful
role that model systems can play in identifying candidate
genes for complex traits. This was the approach taken by
Rosengren et al, who studied a well-characterized animal
model of type 2 diabetes (T2D), the GK rat. They used con-
genic strainswithvaryingamounts of theGK-derivedmajor
diabetes susceptibility locus to identify a T2D candidate
gene that opened the door to understanding a molecular
pathway involved in T2D. They found that overexpression
of the alpha2A-adrenergic receptor (alpha[2A]AR) in GK
rats was associated with reduced b cell exocytosis as a
result of impaired insulin granule docking at the plasma
membrane. This gene is conserved, and the researchers
found that a similar mechanism holds true in people.
They identiﬁed a SNP in ADRA2A that was associated with
impaired insulin secretion in humans because of hyperac-
tive signaling through alpha(2A)AR. The same SNP was
also associated with T2D in a case-control sample. Previous
studies have implicated alpha(2A)AR in control of blood
pressure and in adipocyte function. Because heart disease,
diabetes, and stroke are all parts of themetabolic syndrome
seen in overweight individuals, this receptor could be part
of a central pathway relevant to this disorder.
Rosengren et al. (2009) Overexpression of alpha2A-adrenergic
receptors contributes to type 2 diabetes. Science Express. Pub-
lished online November 19, 2009. 10.1126/science.1176827.This Month in Our Sister JournalsMutational Analysis of EDNRB and EDN3
in Hirschsprung Disease
Hirschsprung disease (HSCR) is a developmental defect in
which the intestinal tract is not completely innervated.
Although it can be inherited as part of a syndrome—for
example, there is a 100-fold increased risk of HSCR associ-
ated with Down syndrome—sporadic, nonsyndromic
HSCR also occurs. Two signaling pathways involved in
the development of the enteric nervous system are known
to play roles in HSCR: the RET signaling pathway and
the endothelin-3 (EDN3)/endothelin receptor B (EDNRB)
pathway. Sanchez-Mejias et al. were interested in further
deﬁning the role of genetic variation in EDN3 and EDNRB
in the development of HSCR. They screened both genes in
196peoplewithHSCRand identiﬁedvariants inbothgenes.
These variants included a nonsense mutation in an exon 50
to the previously deﬁned exon 1 in EDNRB. This is the ﬁrst
suggestion that this upstream exonmight be important for
HSCR and should be considered further in additional
studies. They also ﬁnd evidence that a speciﬁc EDN3 haplo-type is overrepresented in their case sample, and they argue
that variations in this gene could be common, low pene-
trance contributors to risk of HSCR. Some of the patients
studied carried more than one HSCR-risk allele. It remains
to be seen how this variation combines to inﬂuence the
development of the enteric nervous system.
Sanchez-Mejias et al. (2009) New roles of EDNRB and EDN3
in the pathogenesis of Hirschsprung disease. Genetics in
Medicine. Published online December 8, 2009. 10.1097/
GIM.0b013e3181c371b0.
How Many Genes for Stripes and Spots?
How does a tiger get its stripes? It’s a question that my four-
year old has asked me, but the truth is that we really don’t
know the answer. We’ve gotten a bit closer with the work
of Eizirik et al., who used domestic cats to understand the
genetics of mammlian coat patterning. Breeding lore
suggested that four basic coat patterns in cats are the result
of four alleles of a single locus,Tabby. Eizirik et al. performed
systematic breeding of cats with these four patterns and
found evidence that there are actually three loci that work
in combination to determine coat patterning. On the basis
of the patterns that theyhave seen in these cats, the authors
propose that coat patterning involves two processes: one in
which the spatial patterns are laid down, then one inwhich
pigmentation patterns are established via the spatialThpatterns. Now, who wants to go breed tigers to see whether
the same thing holds true in that species? Any takers?
Eizirik et al. (2009) Deﬁning and mapping mammalian coat
pattern genes: Multiple genomic regions implicated in domestic
cat stripes and spots. Genetics. Published online October 26,
2009. 10.1534/genetics.109.109629.e American Journal of Human Genetics 86, 3–5, January 8, 2010 5
